Quantum dialysis technologies raised $60 million in a Series E funding round to expand its U.S. commercial presence for its Quanta dialysis system.

The company, which has offices in Beverly, Massachusetts and Warwick, United Kingdom, designed its dialysis system to be compact but with the performance of traditional machines. In 2022, the FDA cleared the system to perform intermittent hemodialysis (IHD), low-efficiency sustained dialysis, and CRRT (CVVHD and SCUF) without the need for bags. Recently there was a additional FDA clearance for home hemodialysisoffering a high dialysate flow system (500 ml/minute).

In addition to an expanded commercial presence in the United States, Quanta officials plan to use the influx of cash to support more innovation.

“Our commitment to providing innovative solutions for acute care has never been stronger,” said Alejandro Galindo, CEO of Quanta, in a press release. “This funding round provides the resources needed to solidify Quanta as a best-in-class solution across the care continuum, to significantly expand our business operations, while continuing to introduce enhancements that will strengthen our long-term competitive position.”

Novo Holdings, Glenview Capital and b2venture led the latest funding round.

“Quanta’s compelling product-market fit in the $1.5 billion acute care segment is demonstrated by its ability to win contracts against established competitors CRRT and IHD,” said Robert Ghenchev, managing partner of growth investments at Novo Holdings. “The recent FDA clearance for the home setting is transformational for patients and significantly expands Quanta’s addressable market into the chronic and subacute segments. »